Literature DB >> 21330193

Analysis of the optimal cut-point for HIV-p24 antigen testing to diagnose HIV infection in HIV-exposed children from resource-constrained settings.

M Tamhane1, B Gautney, C Shiu, N Segaren, L Jeannis, C Eustache, Y Simeon-Fadois, Y H Chen, D De, S Irivinti, P Tamma, C B Thompson, S Khamadi, G K Siberry, D Persaud.   

Abstract

BACKGROUND: Nucleic-acid-testing (NAT) to diagnose HIV infection in children under age 18 months provides a barrier to HIV-testing in exposed children from resource-constrained settings. The ultrasensitive HIV-p24-antigen (Up24) assay is cheaper and easier to perform and is sensitive (84-98%) and specific (98-100%). The cut-point optical density (OD) selected for discriminating between positive and negative samples may need assessment due to regional differences in mother-to-child HIV-transmission rates.
OBJECTIVES: We used receiver operator characteristics (ROC) curves and logistic regression analyses to assess the effect of various cut-points on the diagnostic performance of Up24 for HIV-infection status among HIV-exposed children. Positive and negative predictive values at different rates of disease prevalence were also estimated. STUDY
DESIGN: A study of Up24 testing on dried blood spot (DBS) samples collected from 278 HIV-exposed Haitian children, 3-24-months of age, in whom HIV-infection status was determined by NAT on the same DBS card.
RESULTS: The sensitivity and specificity of Up24 varied by the cut-point-OD value selected. At a cut-point-OD of 8-fold the standard deviation of the negative control (NCSD), sensitivity and specificity of Up24 were maximized [87.8% (95% CI, 83.9-91.6) and 92% (95% CI, 88.8-95.2), respectively]. In lower prevalence settings (5%), positive and negative predictive values of Up24 were maximal (75.9% and 98.8%, respectively) at a cut-point-OD that was 15-fold the NCSD.
CONCLUSIONS: In low prevalence settings, a high degree of specificity can be achieved with Up24 testing of HIV-exposed children when a higher cut-point OD is used; a feature that may facilitate more frequent use of Up24 antigen testing for HIV-exposed children.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21330193      PMCID: PMC3065028          DOI: 10.1016/j.jcv.2011.01.012

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  18 in total

1.  Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples.

Authors:  Enrique F Schisterman; Neil J Perkins; Aiyi Liu; Howard Bondell
Journal:  Epidemiology       Date:  2005-01       Impact factor: 4.822

2.  Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings.

Authors:  Richard A Respess; Ada Cachafeiro; David Withum; Susan A Fiscus; Daniel Newman; Bernard Branson; Oliviero E Varnier; Kim Lewis; Timothy J Dondero
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings.

Authors:  Marlyse C Knuchel; Zuzana Tomasik; Roberto F Speck; Ruedi Lüthy; Jörg Schüpbach
Journal:  J Clin Virol       Date:  2006-01-23       Impact factor: 3.168

4.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

5.  p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection.

Authors:  Ruengpung Sutthent; Narintorn Gaudart; Kulkanya Chokpaibulkit; Nattaya Tanliang; Chinda Kanoksinsombath; Pongsakdi Chaisilwatana
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

6.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

7.  Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole-blood spots as a reliable, affordable test for infant diagnosis.

Authors:  Janet C Patton; Gayle G Sherman; Ashraf H Coovadia; Wendy S Stevens; Tammy M Meyers
Journal:  Clin Vaccine Immunol       Date:  2006-01

8.  Using a simplified human immunodeficiency virus type 1 p24 antigen assay to diagnose pediatric HIV-infection in Malawi.

Authors:  Victor Mwapasa; Ada Cachafeiro; Yohane Makuta; David J Beckstead; Michael L Pennell; Ben Chilima; Beatrice Mwagomba; Susan A Fiscus; Jesse J Kwiek
Journal:  J Clin Virol       Date:  2010-09-19       Impact factor: 3.168

9.  Pediatric human immunodeficiency virus screening in an African district hospital.

Authors:  A J De Baets; B S Edidi; M J Kasali; G Beelaert; W Schrooten; A Litzroth; P Kolsteren; D Denolf; K Fransen
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

10.  Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants. Swiss Neonatal HIV Study Group.

Authors:  J Schüpbach; J Böni; Z Tomasik; J Jendis; R Seger; C Kind
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

View more
  2 in total

Review 1.  p24 revisited: a landscape review of antigen detection for early HIV diagnosis.

Authors:  Eleanor R Gray; Robert Bain; Olivia Varsaneux; Rosanna W Peeling; Molly M Stevens; Rachel A McKendry
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

2.  Early Infant Diagnosis Sample Management in Mashonaland West Province, Zimbabwe, 2017.

Authors:  Hamufare Mugauri; Owen Mugurungi; Addmore Chadambuka; Tsitsi Juru; Notion Tafara Gombe; Gerald Shambira; Mufuta Tshimanga
Journal:  AIDS Res Treat       Date:  2018-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.